- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02469532
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or atherectomy-based revascularization procedures.
- To observe the femoropopliteal revascularization outcomes post-angioplasty and/or atherectomy and to observe potential correlation between patency outcomes and the levels of MCP-1, C-reactive protein and MMP-9 from baseline to 24 hours and 30 days post-procedure.
- To provide a comparator dataset to the investigational DANCE trial, which has the same enrollment criteria as this observational trial but includes the investigational use of a local drug therapy to limit inflammation caused by mechanical revascularization.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Arkansas Heart Hospital
-
-
Louisiana
-
Bossier City, Louisiana, Estados Unidos, 7111
- Endovascular Technologies (Willis Knighton Medical Center)
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Hattiesburg Clinic
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos
- Rex Hospital
-
-
Texas
-
New Braunfels, Texas, Estados Unidos, 78130
- Mission Research Institute
-
Palestine, Texas, Estados Unidos, 75801
- Palestine Regional Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
Screening Criteria
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb.
- Patient is willing to provide informed consent and comply with the required follow up visits Procedural Criteria
- De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
- >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3mm and ≤ 8mm
- Successful wire crossing of lesion
- A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)
Exclusion Criteria:
Screening Criteria
- Pregnant, nursing or planning on becoming pregnant in < 2years
- Life expectancy of <2 years
- Known active malignancy
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR <29
- Prior bypass surgery, drug-coated balloon or stenting of the target lesion
- Contra-indication or known hypersensitivity to contrast media or physician prescribed antiplatelet regimen as applicable
- Systemic fungal infection
- Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
- Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
- Acute limb ischemia
- Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
- Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial Procedural Criteria
- Lesions extending into the trifurcation or above the profunda
- Heavy eccentric or moderate circumferential calcification at index lesion
- Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
- Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
- Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Atherectomy
Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures. |
Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
|
|
Angioplasty
Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures. |
Device: Balloon Angioplasty Selection is driven by preference of the operator
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in inflammatory biomarkers
Prazo: Baseline to 24-hours post-procedure and 30-days post-procedure
|
Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
|
Baseline to 24-hours post-procedure and 30-days post-procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Target Lesion Revascularization
Prazo: 6 and 12 months post-procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the restenosis rates in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
|
6 and 12 months post-procedure
|
|
Comparing biomarker (hs-CRP, MCP-1 and MMP-9) results
Prazo: Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the correlation between the levels of MCP-1, C-reactive protein and MMP-9 after angioplasty or atherectomy procedures in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
Objective measurement of biomarkers will be performed by a contract laboratory to avoid bias.
|
Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jason A Yoho, MD, Mission Research, New Braunfels, TX
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CIP0181
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença arterial periférica
-
Mayo ClinicInscrevendo-se por conviteAnatomia da GSV para Rescue Peripheral IV AccessEstados Unidos
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeConcluídoPressão arterial | Anestesia | Linha arterialEstados Unidos
-
GE HealthcareRecrutamentoMedição da pressão arterial | Pressão arterialFinlândia
-
GE HealthcareConcluído
-
Taiwan Biophotonic CorporationConcluídoPressão arterial | Variabilidade da pressão arterialTaiwan
-
VIVUS LLCAinda não está recrutandoHipertensão arterial pulmonar | Hipertensão Arterial Pulmonar (HAP) (OMS Grupo 1 HP) | Hipertensão Arterial Pulmonar (HAP) | Hipertensão Arterial Pulmonar Grupo I da OMS | Hipertensão Arterial Pulmonar HAP
-
AHEPA University HospitalConcluídoRigidez Arterial | Monitorização Ambulatorial da Pressão ArterialGrécia
-
BLZ Technology (Wuhan) Co.,LtdAinda não está recrutandoPressão arterial | Anestesia geral | Linha arterial | Pulsação
-
Shunmei MedicalAinda não está recrutandoDoença Arterial Coronária Calcificada | Doença arterial coronarianaPolônia, França, Espanha
-
Auburn UniversityConcluídoDorme | Pressão arterial | Disfunção Endotelial | Racismo | Rigidez ArterialEstados Unidos
Ensaios clínicos em Atherectomy System
-
Reciprocal LabsCalifornia HealthCare FoundationConcluído
-
Muş Alparlan UniversityRecrutamentoMarcha, EspásticaPeru
-
ContinUse Biometrics Ltd.Concluído
-
St. Joseph's Healthcare HamiltonRecrutamentoTranstorno neurocognitivo leveCanadá
-
Boston Scientific CorporationConcluídoDoenças pancreáticas | Doenças das vias biliares | Doença HepáticaEstados Unidos, Índia, Hong Kong, China
-
SpineSave AGRecrutamentoEspondilartrite | Instabilidade Coluna Lombar | Espondilolistese Degenerativa | Estenose Espinhal Lombar Degenerativa | Discopatia | Artrose da Articulação FacetáriaSuíça
-
Neo Medical SAConfinisCPMAtivo, não recrutandoTrauma | Doença degenerativa do disco | Estenose espinal | Espondilolistese | Tumor Espinhal | Pseudoartrose da Coluna VertebralAlemanha, Espanha
-
ENTire Medical Ltd.Concluído
-
Medtronic MiniMed, Inc.Ainda não está recrutandoDiabetes tipo 1 (T1D)Espanha, França, Reino Unido, Itália, Alemanha, Holanda
-
ReVivo Medical, Corp.The Cleveland Clinic; Albany Medical College; IGEARecrutamentoDor de pescoço | Espondilose | Espondilose Com Mielopatia | Espondilose com Radiculopatia | Espondilose com Radiculopatia Região Cervical | Distúrbio do Disco Intervertebral CervicalEstados Unidos